These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39102671)

  • 1. Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective.
    Das A; Gkoutos GV; Acharjee A
    Cancer Med; 2024 Jan; 13(1):e6945. PubMed ID: 39102671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss-of-function mutation of REV1 (p.R704Q) mediates cetuximab primary resistance by activating autophagy in RAS-wild type metastatic colorectal cancer.
    Zhu N; Ding Y; Mi M; Yang J; Yang M; Li D; Zhang Y; Fang X; Weng S; Yuan Y
    Cancer Lett; 2024 Aug; 598():217103. PubMed ID: 38969162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
    Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of double-strand break repair, translesion synthesis, and interstrand crosslinks in colorectal cancer progression-clinicopathological data and survival.
    Laporte GA; Leguisamo NM; Gloria HCE; Azambuja DB; Kalil AN; Saffi J
    J Surg Oncol; 2020 Apr; 121(5):906-916. PubMed ID: 31650563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells.
    Latancia MT; Leandro GDS; Bastos AU; Moreno NC; Ariwoola AA; Martins DJ; Ashton NW; Ribeiro VC; Hoch NC; Rocha CRR; Woodgate R; Menck CFM
    DNA Repair (Amst); 2024 Sep; 141():103715. PubMed ID: 39029375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
    Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
    Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
    [No Abstract]   [Full Text] [Related]  

  • 8. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer.
    Luo M; Huang Z; Yang X; Chen Y; Jiang J; Zhang L; Zhou L; Qin S; Jin P; Fu S; Peng L; Li B; Fang Y; Pu W; Gong Y; Liu Y; Ren Z; Liu QL; Wang C; Xiao F; He D; Zhang H; Li C; Xu H; Dai L; Peng Y; Zhou ZG; Huang C; Chen HN
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1223-1242. PubMed ID: 34952201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
    Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
    Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
    Woolston A; Khan K; Spain G; Barber LJ; Griffiths B; Gonzalez-Exposito R; Hornsteiner L; Punta M; Patil Y; Newey A; Mansukhani S; Davies MN; Furness A; Sclafani F; Peckitt C; Jiménez M; Kouvelakis K; Ranftl R; Begum R; Rana I; Thomas J; Bryant A; Quezada S; Wotherspoon A; Khan N; Fotiadis N; Marafioti T; Powles T; Lise S; Calvo F; Guettler S; von Loga K; Rao S; Watkins D; Starling N; Chau I; Sadanandam A; Cunningham D; Gerlinger M
    Cancer Cell; 2019 Jul; 36(1):35-50.e9. PubMed ID: 31287991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
    Li C; Singh B; Graves-Deal R; Ma H; Starchenko A; Fry WH; Lu Y; Wang Y; Bogatcheva G; Khan MP; Milne GL; Zhao S; Ayers GD; Li N; Hu H; Washington MK; Yeatman TJ; McDonald OG; Liu Q; Coffey RJ
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2852-E2861. PubMed ID: 28320945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
    Mason JD; Marks E; Fan SJ; McCormick K; Wilson C; Harris AL; Hamdy FC; Cunningham C; Goberdhan DCI
    J Extracell Vesicles; 2024 Jun; 13(6):e12465. PubMed ID: 38887984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3.
    Peng C; Li X; Yao Y; Nie Y; Fan L; Zhu C
    Cancer Biol Ther; 2024 Dec; 25(1):2373497. PubMed ID: 38967961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
    Andrijes R; Hejmadi RK; Pugh M; Rajesh S; Novitskaya V; Ibrahim M; Overduin M; Tselepis C; Middleton GW; Győrffy B; Beggs AD; Berditchevski F
    Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34521767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.
    Zhang X; Zhou W; Wu C; Jiang J; Guo Q; Feng L; Cheng X; Zhang X
    Sci Rep; 2024 May; 14(1):10642. PubMed ID: 38724565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer.
    Xu X; Liu M; Peng K; Yu Y; Liu T
    Clin Transl Oncol; 2023 Mar; 25(3):776-785. PubMed ID: 36609651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.